Flerobuterol

Flerobuterol
Clinical data
Other names	CRL-40827
Drug class	β-Adrenergic receptor agonist
Identifiers
	IUPAC name 2-(tert-butylamino)-1-(2-fluorophenyl)ethanol;
CAS Number	82101-10-8;
PubChem CID	71254;
ChemSpider	64385;
UNII	F05RR5M463;
ChEMBL	ChEMBL2106772;
CompTox Dashboard (EPA)	DTXSID80868640 ;
Chemical and physical data
Formula	C12H18FNO
Molar mass	211.280 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)NCC(C1=CC=CC=C1F)O;
	InChI InChI=1S/C12H18FNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3; Key:XTJMTDZHCLBKFU-UHFFFAOYSA-N;

Flerobuterol (INNTooltip International Nonproprietary Name; developmental code name CRL-40827) is a selective β-adrenergic receptor agonist related to salbutamol which was under development for the treatment of major depressive disorder but was never marketed. It is an agonist of the β₁-, β₂-, and β₃-adrenergic receptors. The drug was under development in France by Cephalon and Lafon and reached phase 2 clinical trials prior to its development being discontinued. It was first described in the scientific literature by 1988 and its development was terminated in 2007.